Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vancomycin in primary sclerosing cholangitis: randomized placebo-controlled phase 2 trial
2022-000875-37Phase 2Active
- Sponsor
- University of Milano-Bicocca
- Start
- Aug 2022
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vancomycin in Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by University of Milano-Bicocca. Primary endpoint: Primary endpoint: Alkaline phosphatase levels at 6 months. Started Aug 2022; status: active.
02
Drugs
vancomycin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2022-000875-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000875-37.